The present invention relates to compositions comprising gases, particularly oxygen (O2) in an amount of from about 91% to about 99% by volume, and carbon dioxide (CO2) in an amount of from about 1% to about 9% by volume, based upon the total volume of the composition, and their use in mitigating the negative effects of surgery and/or anaesthesia on a patient.

The present invention relates to compositions comprising gases, particularly oxygen (O2) in an amount of from about 91% to about 99% by volume, and carbon dioxide (CO2) in an amount of from about 1% to about 9% by volume, based upon the total volume of the composition, and their use in mitigating the negative effects of surgery and/or anaesthesia on a patient.

A method of treating spinal cord injuries in a patient using sagittal MR images of the spinal cord injury to guide the extent of exposure of the neuro/orthopedic surgeon during a posterior spinal fusion for the purpose of autologous stem cell therapy in the setting of spinal injury; the method using large volumes of the patient's bone marrow aspirated to yield a large quantity of heterogeneous autologous stem cell concentrate containing cellular and subcellular fractions, in addition to soluble protein factors (defined as heterogeneous concentrate) exhibiting regenerative potential which is then applied directly over the spinal cord (under the dura/arachnoid) in the areas affected.

A compound of formula (I), and racemates, stereoisomers, tautomers, isotopic markers, solvates, polymorphs and oxynitrides of the compound, or a pharmaceutically acceptable salt thereof can be used as JNK inhibitors. A method for preparing the compound of formula (I) and a pharmaceutical composition comprising the compound of formula (I) are provided. The compound of formula (I) can be used for preparing drugs. The resulting drugs are used for treating diseases that can be treated by inhibiting JNK activity.

##STR00001##

The present invention provides a highly safe non-lamellar liquid crystal-forming composition. The present invention relates to a non-lamellar liquid crystal-forming composition comprising a phospholipid and an amphipathic compound represented by the following general formula (I), wherein X and Y each denotes a hydrogen atom or together denote an oxygen atom, n denotes the integer 1 or 2, m denotes the integer 1 or 2, and R denotes a hydrophilic group having one or more hydroxyl groups, and wherein the composition has an increased biocompatibility by the phospholipid.

##STR00001##

High-molecular-weight fucan compositions comprising a therapeutically effective, medically acceptable fucan in a composition comprising wherein the fucan, for example, has a molecular weight distribution in which more than 60% w/w of the composition has a molecular weight above 100 kDa.

High-molecular-weight fucan compositions comprising a therapeutically effective, medically acceptable fucan in a composition comprising wherein the fucan, for example, has a molecular weight distribution in which more than 60% w/w of the composition has a molecular weight above 100 kDa.

Compositions, methods, systems, etc., are provided for modified and/or purified fucans and corresponding fucan-containing compositions that inhibit fibrous adhesions among other advantages. The purified/modified fucans and fucan compositions have a reduced level of non-fucan components or impurities such as those found in a starting fucan composition. Such reduced undesirable components or impurities include, for example, undesired components bound to the fucan and compounds in the composition that are not a part of or bound to the fucan.

Compositions, methods, systems, etc., are provided for modified and/or purified fucans and corresponding fucan-containing compositions that inhibit fibrous adhesions among other advantages. The purified/modified fucans and fucan compositions have a reduced level of non-fucan components or impurities such as those found in a starting fucan composition. Such reduced undesirable components or impurities include, for example, undesired components bound to the fucan and compounds in the composition that are not a part of or bound to the fucan.

This disclosure provides a method for improving maturation of an arteriovenous fistula (AVF) in a patient in need of hemodialysis, which method entails applying a solution to the internal wall of a lumen of an AVF; and restoring or initiating blood flow in the AVF, wherein the solution comprises an effective amount of a synthetic proteoglycan comprises a glycan having from about 1 to about 80 collagen-binding peptide(s) bonded to the glycan. Also provided are methods for preparing a vascular graft for a bypass surgery, comprising contacting the internal wall of a section of a blood vessel with a solution comprising an effective amount of the synthetic proteoglycan.